Shanghai Bao Pharma IPO HKEX Raises HK$1 Billion for Biotech Pipeline
Shanghai Bao Pharmaceuticals Co., Ltd. (HKG: 2659) successfully listed on the Hong Kong Stock Exchange...
Bao Pharmaceuticals
Anke Biotech Secures Long‑Acting FSH‑CTP Approval in China
Shanghai Bao Pharmaceuticals Co., Ltd. has received official marketing authorization from China’s National Medical Products Administration (NMPA)...
Shanghai Bao Pharma Files for Hong Kong IPO, Aiming to Boost Biologics Development
Shanghai Bao Pharmaceuticals Co. Ltd., a company leveraging synthetic biology to develop recombinant biologics, submitted...
Anke Bio Secures Exclusive Rights to Bao Pharma’s Long-Acting FSH-CTP for China Market
China-based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) announced an exclusive distribution agreement with...
Shanghai Bao Pharmaceuticals Launches IPO to Advance Biopharmaceutical Pipeline
China-based Shanghai Bao Pharmaceuticals Co., Ltd., a high-end biopharmaceuticals developer, has announced its initial public...
Shanghai Bao Pharmaceutical and Subsidiary Secure Commercialization Rights Deal for SJ02 with Organon China
Shanghai Bao Pharmaceutical, a Chinese pharmaceutical company, along with its wholly-owned subsidiary Suzhou Centergene Pharmaceuticals,...
Shanghai Bao Pharma Raises USD 100M in Series B to Advance Drug Delivery Tech
Shanghai Bao Pharmaceuticals Co., Ltd has raised over USD 100 million in a Series B...